# Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age

> **NCT03165617** · PHASE3 · COMPLETED · sponsor: **Seqirus** · enrollment: 4514 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** QIVc
- **BIOLOGICAL:** Non-influenza Comparator Vaccine

## Key facts

- **NCT ID:** NCT03165617
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-25
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-09-30
- **Target enrollment:** 4514 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03165617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03165617, "Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03165617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*